Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMO sued over contact lens solution

This article was originally published in The Tan Sheet

Executive Summary

Californian Maria Ruiz alleges in a complaint Dec. 22 that Advanced Medical Optics falsely advertised Complete Easy Rub Multi-Purpose Solutionfor contact lens care as a "new" formulation with "enhanced protection" against Acanthamoeba keratitis infections. The complaint, filed in California State Superior Court in Orange County, alleges the Easy Rub formula launched in 2007 is identical to an old formula AMO used in a private-label product, law firm Lieff Cabraser Heimann & Bernstein, counsel for the plaintiff, says in a release. The Easy Rub marketing provides "a false sense of security" since the solution's disinfectant ingredient "is not effective against Acanthamoeba organisms," the law firm adds. Santa Ana, Calif.-based AMO recalled a "no rub" solution in May 2007 after users experienced Acanthamoeba-related eye infections (1"The Tan Sheet" June 23, 2008, p. 12)

You may also be interested in...



Contact Lens Care Solutions Should Require “Rubbing” – FDA Panel

All multipurpose contact lens care solutions should include directions for "rubbing" as well as rinsing to help avoid potential eye infections, including solutions previously approved with "no rub" labels on exterior packaging, FDA's Ophthalmic Devices Panel says

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel